Clinical trial
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
NCT00308607 · University of Turku, Other · Completed
Key facts
| NCT number | NCT00308607 |
|---|---|
| Title | Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma |
| Official title | Bevacizumab, Dacarbazine and Interferon Alfa-2a Combination as a First-Line Therapy in Patients With Locally Advancing or Metastatic Melanoma |
| Lead sponsor | University of Turku, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | Bevacizumab (Avastin), dacarbazine, interferon-alfa-2a (Roferon-A) |
| Enrollment | 27 |
| Start date | Aug 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Mar 29, 2006 |
| Last update posted | Apr 3, 2009 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: